Home / Lifestyle / Health & Fitness / Article / AstraZeneca admits Covishield jab raises TTS risk: Here is everything to know

AstraZeneca admits Covishield jab raises TTS risk: Here is everything to know

In India, almost 90 per cent of people who received Covid-19 vaccine, received the AstraZeneca vaccine which in India is called Covishield

Listen to this article :
Image for representational purposes only. Photo Courtesy: iStock

Image for representational purposes only. Photo Courtesy: iStock

Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca’s Covid vaccine, and the benefits far outweigh the risks of the jab, said doctors here on Tuesday.

This comes after reports said that AstraZeneca has for the first time accepted in court documents that its vaccine, developed in partnership with Oxford University, can raise the risk of a rare and serious blood clot.

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All

Advertisement